Autotaxin, a secreted lysophospholipase D, as a promising therapeutic target in chronic inflammation and cancer

Progress in Lipid Research

Volumn 58, Issue , 2015, Pages 76-96

  Barbayianni, Efrosini ^a   Kaffe, Eleanna ^b   Aidinis, Vassilis ^b   Kokotos, George ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

Author keywords

Autotaxin; Cancer; Inflammation; Inhibitors; Lysophosphatidic acid; Lysophospholipase D

Indexed keywords

1,10 PHENANTHROLINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETAL DERIVATIVE; AUTOTAXIN; AUTOTAXIN INHIBITOR; BMP 22; DEBIO 0719; EDETIC ACID; ETOPOSIDE; FLUDARABINE; GINTONIN; GRI 977143; HA 130; HA 155; HA 219; HYDANTOIN DERIVATIVE; KI 16198; KI 16425; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; OLEYL DERIVATIVE; ONO 8430506; PACLITAXEL; PHOSPHODIESTERASE INHIBITOR; PHOSPHONIC ACID DERIVATIVE; PIPERAZINE DERIVATIVE; S 32826; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VPC 8A 202; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; PHOSPHODIESTERASE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CARDIOVASCULAR DISEASE; CATALYSIS; CHRONIC HEPATITIS; CHRONIC INFLAMMATION; DIABETES MELLITUS; DRUG POTENCY; DRUG RESISTANCE; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; EMBRYO DEVELOPMENT; ENZYME SPECIFICITY; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; IC50; LUNG FIBROSIS; LUNG METASTASIS; MELANOMA; METASTASIS; NEOPLASM; NONHUMAN; OBESITY; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; CHRONIC DISEASE; INFLAMMATION; METABOLISM; NEOPLASMS;

MAMMALIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; EMBRYONIC DEVELOPMENT; HUMANS; INFLAMMATION; NEOPLASMS; PHOSPHORIC DIESTER HYDROLASES; SUBSTRATE SPECIFICITY;

EID: 84925437362     PISSN: 01637827     EISSN: 18732194     Source Type: Journal    
DOI: 10.1016/j.plipres.2015.02.001     Document Type: Review

References (317)

1. M.L. Stracke, H.C. Krutzsch, E.J. Unsworth, A. Arestad, V. Cioce, and E. Schiffmann Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein J Biol Chem 267 1992 2524 2529
2. C. Stefan, S. Jansen, and M. Bollen NPP-type ectophosphodiesterases: unity in diversity Trends Biochem Sci 30 2005 542 550
3. A. Tokumura, E. Majima, Y. Kariya, K. Tominaga, K. Kogure, and K. Yasuda Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase J Biol Chem 277 2002 39436 39442
4. W.H. Moolenaar, L.A. van Meeteren, and B.N.G. Giepmans The ins and outs of lysophosphatidic acid signaling Bioessays 26 2004 870 881
5. K. Noguchi, D. Herr, T. Mutoh, and J. Chun Lysophosphatidic acid (LPA) and its receptors Curr Opin Pharmacol 9 2009 15 23
6. Y.C. Yung, N.C. Stoddard, and J. Chun LPA receptor signaling: pharmacology, physiology, and pathophysiology J Lipid Res 55 2014 1192 1214
7. M.G. Benesch, Y.M. Ko, T.P. McMullen, and D.N. Brindley Autotaxin in the crosshairs: taking aim at cancer and other inflammatory conditions FEBS Lett 588 2014 2712 2727
8. S. Knowlden, and S.N. Georas The Autotaxin-LPA Axis Emerges as a Novel Regulator of Lymphocyte Homing and Inflammation J Immunol 192 2014 851 857
9. M. Gotoh, Y. Fujiwara, J. Yue, J. Liu, S. Lee, and J. Fells Controlling cancer through the autotaxin-lysophosphatidic acid receptor axis Biochem Soc Trans 40 2012 31 36
10. A.J. Houben, and W.H. Moolenaar Autotaxin and LPA receptor signaling in cancer Cancer Metastasis Rev 30 2011 557 565
11. E. Barbayianni, V. Magrioti, P. Moutevelis-Minakakis, and G. Kokotos Autotaxin inhibitors: a patent review Expert Opin Ther Pat 23 2013 1123 1132
12. A. Perrakis, and W.H. Moolenaar Autotaxin: structure-function and signaling J Lipid Res 55 2014 1010 1018
13. S. Jansen, C. Stefan, J.W. Creemers, E. Waelkens, A. Van Eynde, and W. Stalmans Proteolytic maturation and activation of autotaxin (NPP2), a secreted metastasis-enhancing lysophospholipase D J Cell Sci 118 2005 3081 3089
14. S. Koike, K. Keino-Masu, T. Ohto, and M. Masu The N-terminal hydrophobic sequence of autotaxin (ENPP2) functions as a signal peptide Genes Cells 11 2006 133 142
15. J. Murata, H.Y. Lee, T. Clair, H.C. Krutzsch, A.A. Arestad, and M.E. Sobel CDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiesterases J Biol Chem 269 1994 30479 30484
16. A. Giganti, M. Rodriguez, B. Fould, N. Moulharat, F. Coge, and P. Chomarat Murine and human autotaxin alpha, beta, and gamma isoforms: gene organization, tissue distribution, and biochemical characterization J Biol Chem 283 2008 7776 7789
17. T. Hashimoto, S. Okudaira, K. Igarashi, K. Hama, Y. Yatomi, and J. Aoki Identification and biochemical characterization of a novel autotaxin isoform, ATXdelta, with a four-amino acid deletion J Biochem 151 2012 89 97
18. A.J. Houben, X.M. van Wijk, L.A. van Meeteren, L. van Zeijl, E.M. van de Westerlo, and J. Hausmann The polybasic insertion in autotaxin alpha confers specific binding to heparin and cell surface heparan sulfate proteoglycans J Biol Chem 288 2013 510 519
19. M. Narita, J. Goji, H. Nakamura, and K. Sano Molecular cloning, expression, and localization of a brain-specific phosphodiesterase I/nucleotide pyrophosphatase (PD-I alpha) from rat brain J Biol Chem 269 1994 28235 28242
20. H. Kawagoe, M.L. Stracke, H. Nakamura, and K. Sano Expression and transcriptional regulation of the PD-I{alpha}/autotaxin gene in neuroblastoma Cancer Res 57 1997 2516 2521
21. M. Umezu-Goto, Y. Kishi, A. Taira, K. Hama, N. Dohmae, and K. Takio Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production J Cell Biol 158 2002 227 233
22. H. Nishimasu, S. Okudaira, K. Hama, E. Mihara, N. Dohmae, and A. Inoue Crystal structure of autotaxin and insight into GPCR activation by lipid mediators Nat Struct Mol Biol 18 2011 205 212
23. J. Hausmann, S. Kamtekar, E. Christodoulou, J.E. Day, T. Wu, and Z. Fulkerson Structural basis of substrate discrimination and integrin binding by autotaxin Nat Struct Mol Biol 18 2011 198 204
24. J. Hausmann, A. Perrakis, and W.H. Moolenaar Structure-function relationships of autotaxin, a secreted lysophospholipase D Adv Biol Regul 53 2013 112 117
25. W.H. Moolenaar, and A. Perrakis Insights into autotaxin: how to produce and present a lipid mediator Nat Rev Mol Cell Biol 12 2011 674 679
26. H. Nishimasu, R. Ishitani, J. Aoki, and O. Nureki A 3D view of autotaxin Trends Pharmacol Sci 2012
27. D.I. Leavesley, A.S. Kashyap, T. Croll, M. Sivaramakrishnan, A. Shokoohmand, and B.G. Hollier Vitronectin-master controller or micromanager? IUBMB Life 65 2013 807 818
28. Z. Fulkerson, T. Wu, M. Sunkara, C.V. Kooi, A.J. Morris, and S.S. Smyth Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells J Biol Chem 286 2011 34654 34663
29. Z. Pamuklar, L. Federico, S. Liu, M. Umezu-Goto, A. Dong, and M. Panchatcharam Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis J Biol Chem 284 2009 7385 7394
30. J. Zhao, D. He, E. Berdyshev, M. Zhong, R. Salgia, and A.J. Morris Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways Biochem J 439 2011 45 55
31. R. Leblanc, S.C. Lee, M. David, J.C. Bordet, D.D. Norman, and R. Patil Interaction of platelet-derived autotaxin with tumor integrin alphaVbeta3 controls metastasis of breast cancer cells to bone Blood 124 2014 3141 3150
32. H. Kanda, R. Newton, R. Klein, Y. Morita, M.D. Gunn, and S.D. Rosen Autotaxin, an ectoenzyme that produces lysophosphatidic acid, promotes the entry of lymphocytes into secondary lymphoid organs Nat Immunol 9 2008 415 423
33. H.Y. Lee, T. Clair, P.T. Mulvaney, E.C. Woodhouse, S. Aznavoorian, and L.A. Liotta Stimulation of tumor cell motility linked to phosphodiesterase catalytic site of autotaxin J Biol Chem 271 1996 24408 24412
34. L.P. Saunders, W. Cao, W.C. Chang, R.A. Albright, D.T. Braddock, and E.M. De La Cruz Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution J Biol Chem 286 2011 30130 30141
35. E. Koh, T. Clair, E.C. Woodhouse, E. Schiffmann, L. Liotta, and M. Stracke Site-directed mutations in the tumor-associated cytokine, autotaxin, eliminate nucleotide phosphodiesterase, lysophospholipase D, and motogenic activities Cancer Res 63 2003 2042 2045
36. S. Jansen, N. Callewaert, I. Dewerte, M. Andries, H. Ceulemans, and M. Bollen An essential oligomannosidic glycan chain in the catalytic domain of autotaxin, a secreted lysophospholipase-D J Biol Chem 282 2007 11084 11091
37. J.P. Pradere, E. Tarnus, S. Gres, P. Valet, and J.S. Saulnier-Blache Secretion and lysophospholipase D activity of autotaxin by adipocytes are controlled by N-glycosylation and signal peptidase Biochim Biophys Acta 1771 2007 93 102
38. E. Koh, R.W. Bandle, D.D. Roberts, M.L. Stracke, and T. Clair Novel point mutations attenuate autotaxin activity Lipids Health Dis 8 2009 4
39. S. Jansen, M. Andries, R. Derua, E. Waelkens, and M. Bollen Domain interplay mediated by an essential disulfide linkage is critical for the activity and secretion of the metastasis-promoting enzyme autotaxin J Biol Chem 284 2009 14296 14302
40. A. Cimpean, C. Stefan, R. Gijsbers, W. Stalmans, and M. Bollen Substrate-specifying determinants of the nucleotide pyrophosphatases/phosphodiesterases NPP1 and NPP2 Biochem J 381 2004 71 77
41. L.M. Yuelling, and B. Fuss Autotaxin (ATX): A multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties Biochim Biophys Acta 1781 2008 525 530
42. R. Gijsbers, J. Aoki, H. Arai, and M. Bollen The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site FEBS Lett 538 2003 60 64
43. J. Lee, I.D. Jung, S.W. Nam, T. Clair, E.M. Jeong, and S.Y. Hong Enzymatic activation of autotaxin by divalent cations without EF-hand loop region involvement Biochem Pharmacol 62 2001 219 224
44. T. Clair, J. Aoki, E. Koh, R.W. Bandle, S.W. Nam, and M.M. Ptaszynska Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate Cancer Res 63 2003 5446 5453
45. M. Tanaka, S. Okudaira, Y. Kishi, R. Ohkawa, S. Iseki, and M. Ota Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid J Biol Chem 281 2006 25822 25830
46. K. Mizugishi, T. Yamashita, A. Olivera, G.F. Miller, S. Spiegel, and R.L. Proia Essential role for sphingosine kinases in neural and vascular development Mol Cell Biol 25 2005 11113 11121
47. T. Clair, H.Y. Lee, L.A. Liotta, and M.L. Stracke Autotaxin is an exoenzyme possessing 5'-nucleotide phosphodiesterase/ATP pyrophosphatase and ATPase activities J Biol Chem 272 1997 996 1001
48. L.A. van Meeteren, P. Ruurs, E. Christodoulou, J.W. Goding, H. Takakusa, and K. Kikuchi Inhibition of Autotaxin by Lysophosphatidic Acid and Sphingosine 1-Phosphate J Biol Chem 280 2005 21155 21161
49. D. Bachner, M. Ahrens, N. Betat, D. Schrφder, and G. Gross Developmental expression analysis of murine autotaxin (ATX) Mech Dev 84 1999 121 125
50. H. Ohuchi, Y. Hayashibara, H. Matsuda, M. Onoi, M. Mitsumori, and M. Tanaka Diversified expression patterns of autotaxin, a gene for phospholipid-generating enzyme during mouse and chicken development Dev Dyn 236 2007 1134 1143
51. J.W. Choi, and J. Chun Lysophospholipids and their receptors in the central nervous system Biochim Biophys Acta 1831 2012 20 32
52. H. Ohuchi, A. Hamada, H. Matsuda, A. Takagi, M. Tanaka, and J. Aoki Expression patterns of the lysophospholipid receptor genes during mouse early development Dev Dyn 237 2008 3280 3294
53. L.A. van Meeteren, P. Ruurs, C. Stortelers, P. Bouwman, M.A. van Rooijen, and J.P. Pradere Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development Mol Cell Biol 26 2006 5015 5022
54. S. Fotopoulou, N. Oikonomou, E. Grigorieva, I. Nikitopoulou, T. Paparountas, and A. Thanassopoulou ATX expression and LPA signalling are vital for the development of the nervous system Dev Biol 339 2010 451 464
55. K. Nakanaga, K. Hama, K. Kano, T. Sato, H. Yukiura, and A. Inoue Overexpression of autotaxin, a lysophosphatidic acid-producing enzyme, enhances cardia bifida induced by hypo-sphingosine-1-phosphate signaling in zebrafish embryo J Biochem 155 2014 235 241
56. H. Yukiura, K. Hama, K. Nakanaga, M. Tanaka, Y. Asaoka, and S. Okudaira Autotaxin regulates vascular development via multiple lysophosphatidic acid (LPA) receptors in zebrafish J Biol Chem 286 2011 43972 43983
57. W.H. Moolenaar, A.J. Houben, S.J. Lee, and L.A. van Meeteren Autotaxin in embryonic development Biochim Biophys Acta 1831 2012 13 19
58. J.J. Contos, N. Fukushima, J.A. Weiner, D. Kaushal, and J. Chun Requirement for the lpA1 lysophosphatidic acid receptor gene in normal suckling behavior Proc Natl Acad Sci U S A 97 2000 13384 13389
59. J.W. Choi, D.R. Herr, K. Noguchi, Y.C. Yung, C.W. Lee, and T. Mutoh LPA receptors: subtypes and biological actions Annu Rev Pharmacol Toxicol 50 2010 157 186
60. M.E. Lin, R.R. Rivera, and J. Chun Targeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic pain J Biol Chem 287 2012 17608 17617
61. J.J. Contos, I. Ishii, N. Fukushima, M.A. Kingsbury, X. Ye, and S. Kawamura Characterization of lpa(2) (Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2) Mol Cell Biol 22 2002 6921 6929
62. X. Ye, K. Hama, J.J. Contos, B. Anliker, A. Inoue, and M.K. Skinner LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing Nature 435 2005 104 108
63. H. Sumida, K. Noguchi, Y. Kihara, M. Abe, K. Yanagida, and F. Hamano LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis Blood 116 2010 5060 5070
64. Z. Lee, C.T. Cheng, H. Zhang, M.A. Subler, J. Wu, and A. Mukherjee Role of LPA4/p2y9/GPR23 in negative regulation of cell motility Mol Biol Cell 19 2008 5435 5445
65. S. Offermanns, V. Mancino, J.P. Revel, and M.I. Simon Vascular system defects and impaired cell chemokinesis as a result of Galpha13 deficiency Science 275 1997 533 536
66. B. Fuss, H. Baba, T. Phan, V.K. Tuohy, and W.B. Macklin Phosphodiesterase I, a novel adhesion molecule and/or cytokine involved in oligodendrocyte function J Neurosci 17 1997 9095 9103
67. G. Ferry, E. Tellier, A. Try, S. Gres, I. Naime, and M.F. Simon Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity J Biol Chem 278 2003 18162 18169
68. S. Gesta, M.F. Simon, A. Rey, D. Sibrac, A. Girard, and M. Lafontan Secretion of a lysophospholipase D activity by adipocytes: involvement in lysophosphatidic acid synthesis J Lipid Res 43 2002 904 910
69. J. Mazereeuw-Hautier, S. Gres, M. Fanguin, C. Cariven, J. Fauvel, and B. Perret Production of lysophosphatidic acid in blister fluid: involvement of a lysophospholipase D activity J Invest Dermatol 125 2005 421 427
70. B.N. Hammack, K.Y. Fung, S.W. Hunsucker, M.W. Duncan, M.P. Burgoon, and G.P. Owens Proteomic analysis of multiple sclerosis cerebrospinal fluid Mult Scler 10 2004 245 260
71. K. Sato, E. Malchinkhuu, T. Muraki, K. Ishikawa, K. Hayashi, and M. Tosaka Identification of autotaxin as a neurite retraction-inducing factor of PC12 cells in cerebrospinal fluid and its possible sources J Neurochem 92 2005 904 914
72. A. Tokumura, T. Kume, K. Fukuzawa, M. Tahara, K. Tasaka, and J. Aoki Peritoneal fluids from patients with certain gynecologic tumor contain elevated levels of bioactive lysophospholipase D activity Life Sci 80 2007 1641 1649
73. K. Nakamura, M. Nangaku, R. Ohkawa, S. Okubo, H. Yokota, and H. Ikeda Analysis of serum and urinary lysophospholipase D/autotaxin in nephrotic syndrome Clin Chem Lab Med 46 2008 150 151
74. N. Oikonomou, M.A. Mouratis, A. Tzouvelekis, E. Kaffe, C. Valavanis, and G. Vilaras Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis Am J Respir Cell Mol Biol 47 2012 566 574
75. H. Nochi, H. Tomura, M. Tobo, N. Tanaka, K. Sato, and T. Shinozaki Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by synovial fluid of patients with rheumatoid arthritis in fibroblast-like synovial cells J Immunol 181 2008 5111 5119
76. I. Nikitopoulou, N. Oikonomou, E. Karouzakis, I. Sevastou, N. Nikolaidou-Katsaridou, and Z. Zhao Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis J Exp Med 209 2012 925 933
77. R. Dusaulcy, C. Rancoule, S. Gres, E. Wanecq, A. Colom, and C. Guigne Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid J Lipid Res 52 2011 1247 1255
78. J. Aoki, A. Inoue, and S. Okudaira Two pathways for lysophosphatidic acid production Biochim Biophys Acta 1781 2008 513 518
79. C. Magkrioti, and V. Aidinis ATX and LPA signalling in lung pathophysiology World J Respirol 3 2013 77 103
80. I. Sevastou, E. Kaffe, M.A. Mouratis, and V. Aidinis Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes Biochim Biophys Acta 1831 2013 42 60
81. L.A. van Meeteren, and W.H. Moolenaar Regulation and biological activities of the autotaxin-LPA axis Prog Lipid Res 46 2007 145 160
82. F. Gobeil Jr., S.G. Bernier, A. Vazquez-Tello, S. Brault, M.H. Beauchamp, and C. Quiniou Modulation of pro-inflammatory gene expression by nuclear lysophosphatidic acid receptor type-1 J Biol Chem 278 2003 38875 38883
83. J. Zhao, D. He, Y. Su, E. Berdyshev, J. Chun, and V. Natarajan Lysophosphatidic acid receptor 1 modulates lipopolysaccharide-induced inflammation in alveolar epithelial cells and murine lungs Am J Physiol Lung Cell Mol Physiol 301 2011 L547 L556
84. Y. Ward, R. Lake, J.J. Yin, C.D. Heger, M. Raffeld, and P.K. Goldsmith LPA receptor heterodimerizes with CD97 to amplify LPA-initiated RHO-dependent signaling and invasion in prostate cancer cells Cancer Res 71 2011 7301 7311
85. R.T. Dorsam, and J.S. Gutkind G-protein-coupled receptors and cancer Nat Rev Cancer 7 2007 79 94
86. C.R. McCudden, M.D. Hains, R.J. Kimple, D.P. Siderovski, and F.S. Willard G-protein signaling: back to the future Cell Mol Life Sci 62 2005 551 577
87. H. Daub, F.U. Weiss, C. Wallasch, and A. Ullrich Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors Nature 379 1996 557 560
88. B. Schafer, B. Marg, A. Gschwind, and A. Ullrich Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival J Biol Chem 279 2004 47929 47938
89. A. Gschwind, N. Prenzel, and A. Ullrich Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation Cancer Res 62 2002 6329 6336
90. V. Rai, F. Toure, S. Chitayat, R. Pei, F. Song, and Q. Li Lysophosphatidic acid targets vascular and oncogenic pathways via RAGE signaling J Exp Med 209 2012 2339 2350
91. K. Umemura, N. Yamashita, X. Yu, K. Arima, T. Asada, and T. Makifuchi Autotaxin expression is enhanced in frontal cortex of Alzheimer-type dementia patients Neurosci Lett 400 2006 97 100
92. N.E. Savaskan, L. Rocha, M.R. Kotter, A. Baer, G. Lubec, and L.A. van Meeteren Autotaxin (NPP-2) in the brain: cell type-specific expression and regulation during development and after neurotrauma Cell Mol Life Sci 64 2007 230 243
93. T. Nakasaki, T. Tanaka, S. Okudaira, M. Hirosawa, E. Umemoto, and K. Otani Involvement of the lysophosphatidic acid-generating enzyme autotaxin in lymphocyte-endothelial cell interactions Am J Pathol 173 2008 1566 1576
94. J.M. Wu, Y. Xu, N.J. Skill, H. Sheng, Z. Zhao, and M. Yu Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma Mol Cancer 9 2010 71
95. G.K. Hansson Regulation of immune mechanisms in atherosclerosis Ann N Y Acad Sci 947 2001 157 165 discussion 65-6
96. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
97. D.L. Bhatt, P.G. Steg, E.M. Ohman, A.T. Hirsch, Y. Ikeda, and J.L. Mas International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis Jama 295 2006 180 189
98. A. Tokumura, K. Fukuzawa, and H. Tsukatani Effects of synthetic and natural lysophosphatidic acids on the arterial blood pressure of different animal species Lipids 13 1978 572 574
99. X. Chen, X.Y. Yang, N.D. Wang, C. Ding, Y.J. Yang, and Z.J. You Serum lysophosphatidic acid concentrations measured by dot immunogold filtration assay in patients with acute myocardial infarction Scand J Clin Lab Invest 63 2003 497 503
100. E. Rother, R. Brandl, D.L. Baker, P. Goyal, H. Gebhard, and G. Tigyi Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques Circulation 108 2003 741 747
101. M. Bot, I. Bot, R. Lopez-Vales, C.H. van de Lest, J.S. Saulnier-Blache, and J.B. Helms Atherosclerotic lesion progression changes lysophosphatidic acid homeostasis to favor its accumulation Am J Pathol 176 2010 3073 3084
102. W. Siess, K.J. Zangl, M. Essler, M. Bauer, R. Brandl, and C. Corrinth Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions Proc Natl Acad Sci U S A 96 1999 6931 6936
103. A. Tokumura, Y. Kanaya, M. Kitahara, M. Miyake, Y. Yoshioka, and K. Fukuzawa Increased formation of lysophosphatidic acids by lysophospholipase D in serum of hypercholesterolemic rabbits J Lipid Res 43 2002 307 315
104. Z. Zhou, P. Subramanian, G. Sevilmis, B. Globke, O. Soehnlein, and E. Karshovska Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium Cell Metab 13 2011 592 600
105. C. Weber, A. Zernecke, and P. Libby The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models Nat Rev Immunol 8 2008 802 815
106. S. Seewald, A. Sachinidis, R. Dusing, Y. Ko, C. Seul, and P. Epping Lysophosphatidic acid and intracellular signalling in vascular smooth muscle cells Atherosclerosis 130 1997 121 131
107. A. Damirin, H. Tomura, M. Komachi, J.P. Liu, C. Mogi, and M. Tobo Role of lipoprotein-associated lysophospholipids in migratory activity of coronary artery smooth muscle cells Am J Physiol Heart Circ Physiol 292 2007 H2513 H2522
108. C. Chen, L.N. Ochoa, A. Kagan, H. Chai, Z. Liang, and P.H. Lin Lysophosphatidic acid causes endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells Atherosclerosis 222 2012 74 83
109. C.L. Chang, H.Y. Hsu, H.Y. Lin, W. Chiang, and H. Lee Lysophosphatidic acid-induced oxidized low-density lipoprotein uptake is class A scavenger receptor-dependent in macrophages Prostaglandins Other Lipid Mediat 87 2008 20 25
110. C. Zhang, D.L. Baker, S. Yasuda, N. Makarova, L. Balazs, and L.R. Johnson Lysophosphatidic acid induces neointima formation through PPARgamma activation J Exp Med 199 2004 763 774
111. Y. Cheng, N. Makarova, R. Tsukahara, H. Guo, E. Shuyu, and P. Farrar Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR Cell Signal 21 2009 1874 1884
112. P. Valet, C. Pages, O. Jeanneton, D. Daviaud, P. Barbe, and M. Record Alpha2-adrenergic receptor-mediated release of lysophosphatidic acid by adipocytes. A paracrine signal for preadipocyte growth J Clin Invest 101 1998 1431 1438
113. G. Pages, A. Girard, O. Jeanneton, P. Barbe, C. Wolf, and M. Lafontan LPA as a paracrine mediator of adipocyte growth and function Ann N Y Acad Sci 905 2000 159 164
114. J. Boucher, D. Quilliot, J.P. Praderes, M.F. Simon, S. Gres, and C. Guigne Potential involvement of adipocyte insulin resistance in obesity-associated up-regulation of adipocyte lysophospholipase D/autotaxin expression Diabetologia 48 2005 569 577
115. C. Rancoule, R. Dusaulcy, K. Treguer, S. Gres, C. Guigne, and D. Quilliot Depot-specific regulation of autotaxin with obesity in human adipose tissue J Physiol Biochem 68 2012 635 644
116. M.F. Simon, D. Daviaud, J.P. Pradere, S. Gres, C. Guigne, and M. Wabitsch Lysophosphatidic acid inhibits adipocyte differentiation via lysophosphatidic acid 1 receptor-dependent down-regulation of peroxisome proliferator-activated receptor gamma2 J Biol Chem 280 2005 14656 14662
117. L. Federico, H. Ren, P.A. Mueller, T. Wu, S. Liu, and J. Popovic Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice Mol Endocrinol 26 2012 786 797
118. C. Rancoule, C. Attane, S. Gres, A. Fournel, R. Dusaulcy, and C. Bertrand Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice Diabetologia 56 2013 1394 1402
119. C. Rancoule, R. Dusaulcy, K. Treguer, S. Gres, C. Attane, and J.S. Saulnier-Blache Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis Biochimie 96 2014 140 143
120. S. Nishimura, M. Nagasaki, S. Okudaira, J. Aoki, T. Ohmori, and R. Ohkawa ENPP2 contributes to adipose tissue expansion in diet-induced obesity Diabetes 63 2014 4154 4164
121. C. Rancoule, M. Viaud, S. Gres, N. Viguerie, P. Decaunes, and A. Bouloumie Pro-fibrotic activity of lysophosphatidic acid in adipose tissue: in vivo and in vitro evidence Biochim Biophys Acta 1841 2014 88 96
122. I.B. McInnes, and G. Schett The pathogenesis of rheumatoid arthritis N Engl J Med 365 2011 2205 2219
123. U. Muller-Ladner, C. Ospelt, S. Gay, O. Distler, and T. Pap Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts Arthritis Res Ther 9 2007 223
124. S.G. Bourgoin, and C. Zhao Autotaxin and lysophospholipids in rheumatoid arthritis Curr Opin Investig Drugs 11 2010 515 526
125. C. Zhao, M.J. Fernandes, G.D. Prestwich, M. Turgeon, J. Di Battista, and T. Clair Regulation of lysophosphatidic acid receptor expression and function in human synoviocytes: implications for rheumatoid arthritis? Mol Pharmacol 73 2008 587 600
126. B. Orosa, A. Gonzalez, A. Mera, J.J. Gomez-Reino, and C. Conde Lysophosphatidic acid receptor 1 suppression sensitizes rheumatoid fibroblast-like synoviocytes to TNF-induced apoptosis Arthritis Rheum 64 2012 2460 2470
127. V. Aidinis, P. Carninci, M. Armaka, W. Witke, V. Harokopos, and N. Pavelka Cytoskeletal rearrangements in synovial fibroblasts as a novel pathophysiological determinant of modeled rheumatoid arthritis PLoS Genet 1 2005 e48
128. D.R. Cerutis, M. Nogami, J.L. Anderson, J.D. Churchill, D.J. Romberger, and S.I. Rennard Lysophosphatidic acid and EGF stimulate mitogenesis in human airway smooth muscle cells Am J Physiol 273 1997 L10 L15
129. T. Sakai, J.M. de la Pena, and D.F. Mosher Synergism among lysophosphatidic acid, beta1A integrins, and epidermal growth factor or platelet-derived growth factor in mediation of cell migration J Biol Chem 274 1999 15480 15486
130. I. Nikitopoulou, I. Sevastou, D. Madan, G.D. Prestwich, and V. Aidinis A metabolically-stabilized phosphonate analog of lysophosphatidic acid attenuates collagen-induced arthritis PLoS One 8 2013 e70941
131. J.K. Gierse, A. Thorarensen, K. Beltey, E. Bradshaw-Pierce, L. Cortes-Burgos, and T. Hall A Novel Autotaxin Inhibitor Reduces Lysophosphatidic Acid Levels in Plasma and the Site of Inflammation J Pharmacol Exp Ther 334 2010 310 317
132. Y. Miyabe, C. Miyabe, Y. Iwai, A. Takayasu, S. Fukuda, and W. Yokoyama Necessity of lysophosphatidic acid receptor 1 for development of arthritis Arthritis Rheum 65 2013 2037 2047
133. B. Orosa, S. Garcia, P. Martinez, A. Gonzalez, J.J. Gomez-Reino, and C. Conde Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis Ann Rheum Dis 73 2014 298 305
134. T.A. Wynn Integrating mechanisms of pulmonary fibrosis J Exp Med 208 2011 1339 1350
135. A.M. Tager, P. LaCamera, B.S. Shea, G.S. Campanella, M. Selman, and Z. Zhao The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak Nat Med 14 2008 45 54
136. J.S. Swaney, C. Chapman, L.D. Correa, K.J. Stebbins, A.R. Broadhead, and G. Bain Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic Acid type 1 receptor-selective antagonist J Pharmacol Exp Ther 336 2011 693 700
137. J.S. Swaney, C. Chapman, L.D. Correa, K.J. Stebbins, R.A. Bundey, and P.C. Prodanovich A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model Br J Pharmacol 160 2010 1699 1713
138. S.L. Friedman Mechanisms of hepatic fibrogenesis Gastroenterology 134 2008 1655 1669
139. A.E. Kremer, J.J. Martens, W. Kulik, F. Rueff, E.M. Kuiper, and H.R. van Buuren Lysophosphatidic acid is a potential mediator of cholestatic pruritus Gastroenterology 139 2010 1008 1018 18 e1
140. A.E. Kremer, R. van Dijk, P. Leckie, F.G. Schaap, E.M. Kuiper, and T. Mettang Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions Hepatology 56 2012 1391 1400
141. D.M. Schlatzer, J.M. Sugalski, Y. Chen, J. Barnholtz-Sloan, P. Davitkov, and F.E. Hazlett Plasma proteome analysis reveals overlapping, yet distinct mechanisms of immune activation in chronic HCV and HIV infections J Acquir Immune Defic Syndr 63 2013 563 571
142. A.B. Cooper, J. Wu, D. Lu, and M.A. Maluccio Is autotaxin (ENPP2) the link between hepatitis C and hepatocellular cancer? J Gastrointest Surg 11 2007 1628 1634 discussion 34-5
143. N. Watanabe, H. Ikeda, K. Nakamura, R. Ohkawa, Y. Kume, and J. Aoki Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C J Clin Gastroenterol 41 2007 616 623
144. H. Nakagawa, H. Ikeda, K. Nakamura, R. Ohkawa, R. Masuzaki, and R. Tateishi Autotaxin as a novel serum marker of liver fibrosis Clin Chim Acta 412 2011 1201 1206
145. T. Pleli, D. Martin, B. Kronenberger, F. Brunner, V. Koberle, and G. Grammatikos Serum autotaxin is a parameter for the severity of liver cirrhosis and overall survival in patients with liver cirrhosis-a prospective cohort study PLoS One 9 2014 e103532
146. N. Watanabe, H. Ikeda, K. Nakamura, R. Ohkawa, Y. Kume, and T. Tomiya Plasma lysophosphatidic acid level and serum autotaxin activity are increased in liver injury in rats in relation to its severity Life Sci 81 2007 1009 1015
147. H. Ikeda, Y. Yatomi, M. Yanase, H. Satoh, A. Nishihara, and M. Kawabata Effects of lysophosphatidic acid on proliferation of stellate cells and hepatocytes in culture Biochem Biophys Res Commun 248 1998 436 440
148. M. Yanase, H. Ikeda, A. Matsui, H. Maekawa, E. Noiri, and T. Tomiya Lysophosphatidic acid enhances collagen gel contraction by hepatic stellate cells: association with rho-kinase Biochem Biophys Res Commun 277 2000 72 78
149. M. Yanase, H. Ikeda, I. Ogata, A. Matsui, E. Noiri, and T. Tomiya Functional diversity between Rho-kinase- and MLCK-mediated cytoskeletal actions in a myofibroblast-like hepatic stellate cell line Biochem Biophys Res Commun 305 2003 223 228
150. H. Ikeda, K. Nagashima, M. Yanase, T. Tomiya, M. Arai, and Y. Inoue Involvement of Rho/Rho kinase pathway in regulation of apoptosis in rat hepatic stellate cells Am J Physiol Gastrointest Liver Physiol 285 2003 G880 G886
151. F. Gobeil Jr., T. Zhu, S. Brault, A. Geha, A. Vazquez-Tello, and A. Fortier Nitric oxide signaling via nuclearized endothelial nitric-oxide synthase modulates expression of the immediate early genes iNOS and mPGES-1 J Biol Chem 281 2006 16058 16067
152. S. Willier, E. Butt, and T.G. Grunewald Lysophosphatidic acid (LPA) signaling in cell migration and cancer invasion: a focused review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays Biol Cell 105 2013 317 333
153. D.B. Hoelzinger, L. Mariani, J. Weis, T. Woyke, T.J. Berens, and W.S. McDonough Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets Neoplasia 7 2005 7 16
154. D.B. Hoelzinger, M. Nakada, T. Demuth, T. Rosensteel, L.B. Reavie, and M.E. Berens Autotaxin: a secreted autocrine/paracrine factor that promotes glioma invasion J Neurooncol 86 2008 297 309
155. A.J. Muinonen-Martin, O. Susanto, Q. Zhang, E. Smethurst, W.J. Faller, and D.M. Veltman Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal PLoS Biol 12 2014 e1001966
156. J. Azare, A. Doane, K. Leslie, Q. Chang, M. Berishaj, and J. Nnoli Stat3 mediates expression of autotaxin in breast cancer PLoS One 6 2011 e27851
157. M. Spitzner, R. Ebner, H.A. Wolff, B.M. Ghadimi, J. Wienands, and M. Grade STAT3: A Novel Molecular Mediator of Resistance to Chemoradiotherapy Cancers (Basel) 6 2014 1986 2011
158. N. Samadi, C. Gaetano, I.S. Goping, and D.N. Brindley Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis Oncogene 28 2009 1028 1039
159. S.C. Su, X. Hu, P.A. Kenney, M.M. Merrill, K.N. Babaian, and X.Y. Zhang Autotaxin-lysophosphatidic acid signaling axis mediates tumorigenesis and development of acquired resistance to sunitinib in renal cell carcinoma Clin Cancer Res 19 2013 6461 6472
160. E. Shuyu, Y.J. Lai, R. Tsukahara, C.S. Chen, Y. Fujiwara, and J. Yue Lysophosphatidic acid 2 receptor-mediated supramolecular complex formation regulates its antiapoptotic effect J Biol Chem 284 2009 14558 14571
161. G. Venkatraman, M.G. Benesch, X. Tang, J. Dewald, T.P. McMullen, and D.N. Brindley Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment FASEB J 2014 10.1096/fj.14-262659
162. B. Zirn, O. Hartmann, B. Samans, M. Krause, S. Wittmann, and F. Mertens Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters Int J Cancer 118 2006 1954 1962
163. A. Masuda, K. Nakamura, K. Izutsu, K. Igarashi, R. Ohkawa, and M. Jona Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma Br J Haematol 143 2008 60 70
164. N. Yanai, N. Matsui, T. Furusawa, T. Okubo, and M. Obinata Sphingosine-1-phosphate and lysophosphatidic acid trigger invasion of primitive hematopoietic cells into stromal cell layers Blood 96 2000 139 144
165. H. Li, R. Yue, B. Wei, G. Gao, J. Du, and G. Pei Lysophosphatidic acid acts as a nutrient-derived developmental cue to regulate early hematopoiesis EMBO J 33 2014 1383 1396
166. D. Evseenko, B. Latour, W. Richardson, M. Corselli, A. Sahaghian, and S. Cardinal Lysophosphatidic Acid Mediates Myeloid Differentiation within the Human Bone Marrow Microenvironment PLoS One 8 2013 e63718
167. T. Tsujiuchi, M. Araki, M. Hirane, Y. Dong, and N. Fukushima Lysophosphatidic acid receptors in cancer pathobiology Histol Histopathol 29 2014 313 321
168. S.C. Lee, Y. Fujiwara, J. Liu, J. Yue, Y. Shimizu, and D.D. Norman Autotaxin, LPA receptors (1 and 5) exert disparate functions in tumor cells versus the host tissue microenvironment in melanoma invasion and metastasis Mol Cancer Res 13 2015 174 185
169. M. Jankowski Autotaxin: its role in biology of melanoma cells and as a pharmacological target Enzyme Res 2011 2011 194857
170. S. Liu, M. Umezu-Goto, M. Murph, Y. Lu, W. Liu, and F. Zhang Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases Cancer Cell 15 2009 539 550
171. N. Panupinthu, H.Y. Lee, and G.B. Mills Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression Br J Cancer 102 2010 941 946
172. K. Teo, and V.G. Brunton The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer Biochem J 463 2014 157 165
173. S. Lin, D. Wang, S. Iyer, A.M. Ghaleb, H. Shim, and V.W. Yang The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer Gastroenterology 136 2009 1711 1720
174. M. David, E. Wannecq, F. Descotes, S. Jansen, B. Deux, and J. Ribeiro Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts PLoS One 5 2010 e9741
175. A. Boucharaba, C.M. Serre, S. Gres, J.S. Saulnier-Blache, J.C. Bordet, and J. Guglielmi Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer J Clin Invest 114 2004 1714 1725
176. A. Boucharaba, C.M. Serre, J. Guglielmi, J.C. Bordet, P. Clezardin, and O. Peyruchaud The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases Proc Natl Acad Sci U S A 103 2006 9643 9648
177. T. Eichholtz, K. Jalink, I. Fahrenfort, and W.H. Moolenaar The bioactive phospholipid lysophosphatidic acid is released from activated platelets Biochem J 291 Pt 3 1993 677 680
178. L.J. Gay, and B. Felding-Habermann Contribution of platelets to tumour metastasis Nat Rev Cancer 11 2011 123 134
179. O. Peyruchaud Novel implications for lysophospholipids, lysophosphatidic acid and sphingosine 1-phosphate, as drug targets in cancer Anticancer Agents Med Chem 9 2009 381 391
180. O. Peyruchaud, R. Leblanc, and M. David Pleiotropic activity of lysophosphatidic acid in bone metastasis Biochim Biophys Acta 1831 2013 99 104
181. D. Hanahan Weinberg Robert A. Hallmarks of cancer: the next generation Cell 144 2014 646 674
182. J. Radeff-Huang, T.M. Seasholtz, R.G. Matteo, and J.H. Brown G protein mediated signaling pathways in lysophospholipid induced cell proliferation and survival J Cell Biochem 92 2004 949 966
183. V. Radhika, J. Hee Ha, M. Jayaraman, S.T. Tsim, and N. Dhanasekaran Mitogenic signaling by lysophosphatidic acid (LPA) involves Galpha12 Oncogene 24 2005 4597 4603
184. J.H. Ha, J.D. Ward, L. Varadarajalu, S.G. Kim, and D.N. Dhanasekaran The gep proto-oncogene Galpha12 mediates LPA-stimulated activation of CREB in ovarian cancer cells Cell Signal 26 2014 122 132
185. S.J. Lee, Y.R. No, D.T. Dang, L.H. Dang, V.W. Yang, and H. Shim Regulation of hypoxia-inducible factor 1alpha (HIF-1alpha) by lysophosphatidic acid is dependent on interplay between p53 and Kruppel-like factor 5 J Biol Chem 288 2013 25244 25253
186. H. Zhang, A. Bialkowska, R. Rusovici, S. Chanchevalap, H. Shim, and J.P. Katz Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Kruppel-like factor 5 J Biol Chem 282 2007 15541 15549
187. S.H. Shin, Y.W. Kwon, S.C. Heo, G.O. Jeong, B.R. Kim, and E.J. Seo Kruppel-like factor 4 mediates lysophosphatidic acid-stimulated migration and proliferation of PC3M prostate cancer cells Exp Mol Med 46 2014 e104
188. M. Kamrava, F. Simpkins, E. Alejandro, C. Michener, E. Meltzer, and E.C. Kohn Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer Oncogene 24 2005 7084 7093
189. M. Yang, W.W. Zhong, N. Srivastava, A. Slavin, J. Yang, and T. Hoey G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the {beta}-catenin pathway Proc Natl Acad Sci U S A 102 2005 6027 6032
190. J.N. Anastas, and R.T. Moon WNT signalling pathways as therapeutic targets in cancer Nat Rev Cancer 13 2013 11 26
191. B. Zirn, B. Samans, S. Wittmann, T. Pietsch, I. Leuschner, and N. Graf Target genes of the WNT/beta-catenin pathway in Wilms tumors Genes Chromosomes Cancer 45 2006 565 574
192. S.L. Lai, W.L. Yao, K.C. Tsao, A.J. Houben, H.M. Albers, and H. Ovaa Autotaxin/Lpar3 signaling regulates Kupffer's vesicle formation and left-right asymmetry in zebrafish Development 139 2012 4439 4448
193. M.M. Murph, J. Hurst-Kennedy, V. Newton, D.N. Brindley, and H. Radhakrishna Lysophosphatidic acid decreases the nuclear localization and cellular abundance of the p53 tumor suppressor in A549 lung carcinoma cells Mol Cancer Res 5 2007 1201 1211
194. J. Hurst-Kennedy, M. Zhong, V. Gupta, B.D. Boyan, and Z. Schwartz 24R,25-Dihydroxyvitamin D3, lysophosphatidic acid, and p53: a signaling axis in the inhibition of phosphate-induced chondrocyte apoptosis J Steroid Biochem Mol Biol 122 2010 264 271
195. R.M. Kortlever, T.R. Brummelkamp, L.A. van Meeteren, W.H. Moolenaar, and R. Bernards Suppression of the p53-dependent replicative senescence response by lysophosphatidic acid signaling Mol Cancer Res 6 2008 1452 1460
196. J. Wu, A. Mukherjee, D.A. Lebman, and X. Fang Lysophosphatidic acid-induced p21Waf1 expression mediates the cytostatic response of breast and ovarian cancer cells to TGFbeta Mol Cancer Res 9 2011 1562 1570
197. X. Ye, I. Ishii, M.A. Kingsbury, and J. Chun Lysophosphatidic acid as a novel cell survival/apoptotic factor Biochim Biophys Acta 1585 2002 108 113
198. Y.C. Kang, K.M. Kim, K.S. Lee, S. Namkoong, S.J. Lee, and J.A. Han Serum bioactive lysophospholipids prevent TRAIL-induced apoptosis via PI3K/Akt-dependent cFLIP expression and Bad phosphorylation Cell Death Differ 11 2004 1287 1298
199. G.V. Raj, J.A. Sekula, R. Guo, J.F. Madden, and Y. Daaka Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB Prostate 61 2004 105 113
200. Y. Meng, S. Kang, J. So, S. Reierstad, and D.A. Fishman Translocation of Fas by LPA prevents ovarian cancer cells from anti-Fas-induced apoptosis Gynecol Oncol 96 2005 462 469
201. Y. Meng, S. Kang, and D.A. Fishman Lysophosphatidic acid inhibits anti-Fas-mediated apoptosis enhanced by actin depolymerization in epithelial ovarian cancer FEBS Lett 579 2005 1311 1319
202. S. Kang, R. Luo, Y. Smicun, D.A. Fishman, and Y. Meng Selective induction of cyclooxygenase-2 plays a role in lysophosphatidic acid regulated Fas ligand cell surface presentation FEBS Lett 580 2006 443 449
203. Y.J. Lai, V.T. Lin, Y. Zheng, E.N. Benveniste, and F.T. Lin The adaptor protein TRIP6 antagonizes Fas-induced apoptosis but promotes its effect on cell migration Mol Cell Biol 30 2010 5582 5596
204. R. Rusovici, A. Ghaleb, H. Shim, V.W. Yang, and C.C. Yun Lysophosphatidic acid prevents apoptosis of Caco-2 colon cancer cells via activation of mitogen-activated protein kinase and phosphorylation of Bad Biochim Biophys Acta 1770 2007 1194 1203
205. F.T. Lin, Y.J. Lai, N. Makarova, G. Tigyi, and W.C. Lin The lysophosphatidic acid 2 receptor mediates down-regulation of Siva-1 to promote cell survival J Biol Chem 282 2007 37759 37769
206. S. E, Y.J. Lai, R. Tsukahara, C.S. Chen, Y. Fujiwara, and J. Yue Lysophosphatidic acid 2 receptor-mediated supramolecular complex formation regulates its antiapoptotic effect J Biol Chem 284 2009 14558 14571
207. X. Hu, F.J. Mendoza, J. Sun, V. Banerji, J.B. Johnston, and S.B. Gibson Lysophosphatidic acid (LPA) induces the expression of VEGF leading to protection against apoptosis in B-cell derived malignancies Cell Signal 20 2008 1198 1208
208. G. Ishdorj, B.A. Graham, X. Hu, J. Chen, J.B. Johnston, and X. Fang Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC J Biol Chem 283 2008 16818 16829
209. J. Hurst-Kennedy, B.D. Boyan, and Z. Schwartz Lysophosphatidic acid signaling promotes proliferation, differentiation, and cell survival in rat growth plate chondrocytes Biochim Biophys Acta 1793 2009 836 846
210. Y. Sun, J.S. Nam, D.H. Han, N.H. Kim, H.K. Choi, and J.K. Lee Lysophosphatidic acid induces upregulation of Mcl-1 and protects apoptosis in a PTX-dependent manner in H19-7 cells Cell Signal 22 2010 484 494
211. D.N. Brindley, F.T. Lin, and G.J. Tigyi Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy Biochim Biophys Acta 1831 2012 74 85
212. X. Hu, N. Haney, D. Kropp, A.F. Kabore, J.B. Johnston, and S.B. Gibson Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB J Biol Chem 280 2005 9498 9508
213. S.W. Nam, T. Clair, C.K. Campo, H.Y. Lee, L.A. Liotta, and M.L. Stracke Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells Oncogene 19 2000 241 247
214. C.I. Lin, C.N. Chen, M.T. Huang, S.J. Lee, C.H. Lin, and C.C. Chang Lysophosphatidic acid up-regulates vascular endothelial growth factor-C and lymphatic marker expressions in human endothelial cells Cell Mol Life Sci 65 2008 2740 2751
215. M.M. Ptaszynska, M.L. Pendrak, R.W. Bandle, M.L. Stracke, and D.D. Roberts Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells Mol Cancer Res 6 2008 352 363
216. P.Y. Wu, Y.C. Lin, S.Y. Lan, Y.L. Huang, and H. Lee Aromatic hydrocarbon receptor inhibits lysophosphatidic acid-induced vascular endothelial growth factor-A expression in PC-3 prostate cancer cells Biochem Biophys Res Commun 437 2013 440 445
217. Y.L. Hu, M.K. Tee, E.J. Goetzl, N. Auersperg, G.B. Mills, and N. Ferrara Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells J Natl Cancer Inst 93 2001 762 768
218. M.M. Ptaszynska, M.L. Pendrak, M.L. Stracke, and D.D. Roberts Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration Mol Cancer Res 8 2010 309 321
219. J. Symowicz, B.P. Adley, M.M. Woo, N. Auersperg, L.G. Hudson, and M.S. Stack Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells Cancer Res 65 2005 2234 2242
220. S.Y. Yang, J. Lee, C.G. Park, S. Kim, S. Hong, and H.C. Chung Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells Clin Exp Metastasis 19 2002 603 608
221. J. Du, C. Sun, Z. Hu, Y. Yang, Y. Zhu, and D. Zheng Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling PLoS One 5 2010 e15940
222. T.T. Li, M. Alemayehu, A.I. Aziziyeh, C. Pape, M. Pampillo, and L.M. Postovit Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells Mol Cancer Res 7 2009 1064 1077
223. J.H. Kim, and R.S. Adelstein LPA(1) -induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells J Cell Physiol 226 2011 2881 2893
224. S. Sengupta, K.S. Kim, M.P. Berk, R. Oates, P. Escobar, and J. Belinson Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion Oncogene 26 2007 2894 2901
225. K.S. Kim, S. Sengupta, M. Berk, Y.G. Kwak, P.F. Escobar, and J. Belinson Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo Cancer Res 66 2006 7983 7990
226. Z. Lee, R.F. Swaby, Y. Liang, S. Yu, S. Liu, and K.H. Lu Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer Cancer Res 66 2006 2740 2748
227. T.B. Pustilnik, V. Estrella, J.R. Wiener, M. Mao, A. Eder, and M.A. Watt Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells Clin Cancer Res 5 1999 3704 3710
228. C. Mahanivong, H.M. Chen, S.W. Yee, Z.K. Pan, Z. Dong, and S. Huang Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells Oncogene 27 2008 1273 1280
229. D.A. Fishman, Y. Liu, S.M. Ellerbroek, and M.S. Stack Lysophosphatidic acid promotes matrix metalloproteinase (MMP) activation and MMP-dependent invasion in ovarian cancer cells Cancer Res 61 2001 3194 3199
230. D. Bian, C. Mahanivong, J. Yu, S.M. Frisch, Z.K. Pan, and R.D. Ye The G12/13-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration Oncogene 25 2006 2234 2244
231. K.J. Jeong, S.Y. Park, K.H. Cho, J.S. Sohn, J. Lee, and Y.K. Kim The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion Oncogene 31 2012 4279 4289
232. Y. Liu, R. Burkhalter, J. Symowicz, K. Chaffin, S. Ellerbroek, and M.S. Stack Lysophosphatidic Acid disrupts junctional integrity and epithelial cohesion in ovarian cancer cells J Oncol 2012 2012 501492
233. E.K. Kim, J.M. Park, S. Lim, J.W. Choi, H.S. Kim, and H. Seok Activation of AMP-activated protein kinase is essential for lysophosphatidic acid-induced cell migration in ovarian cancer cells J Biol Chem 286 2011 24036 24045
234. S. Yu, M.M. Murph, Y. Lu, S. Liu, H.S. Hall, and J. Liu Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells J Natl Cancer Inst 100 2008 1630 1642
235. S.Y. Park, K.J. Jeong, N. Panupinthu, S. Yu, J. Lee, and J.W. Han Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression Oncogene 30 2011 1351 1359
236. S. Liu, M. Murph, N. Panupinthu, and G.B. Mills ATX-LPA receptor axis in inflammation and cancer Cell Cycle 8 2009 3695 3701
237. D.A. Tice, W. Szeto, I. Soloviev, B. Rubinfeld, S.E. Fong, and D.L. Dugger Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling J Biol Chem 277 2002 14329 14335
238. E.J. Black, T. Clair, J. Delrow, P. Neiman, and D.A. Gillespie Microarray analysis identifies Autotaxin, a tumour cell motility and angiogenic factor with lysophospholipase D activity, as a specific target of cell transformation by v-Jun Oncogene 23 2004 2357 2366
239. T.M. Williams, M.E. Williams, R. Kuick, D. Misek, K. McDonagh, and S. Hanash Candidate downstream regulated genes of HOX group 13 transcription factors with and without monomeric DNA binding capability Dev Biol 279 2005 462 480
240. W.T. Wu, C.N. Chen, C.I. Lin, J.H. Chen, and H. Lee Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells Endocrinology 146 2005 3387 3400
241. R.R. Braeuer, M. Zigler, T. Kamiya, A.S. Dobroff, L. Huang, and W. Choi Galectin-3 contributes to melanoma growth and metastasis via regulation of NFAT1 and autotaxin Cancer Res 72 2012 5757 5766
242. P. Conrotto, U. Andreasson, V. Kuci, C.A. Borrebaeck, and S. Ek Knock-down of SOX11 induces autotaxin-dependent increase in proliferation in vitro and more aggressive tumors in vivo Mol Oncol 5 2011 527 537
243. S. Li, B. Wang, Y. Xu, and J. Zhang Autotaxin is induced by TSA through HDAC3 and HDAC7 inhibition and antagonizes the TSA-induced cell apoptosis Mol Cancer 10 2011 18
244. S. Kadekar, I. Silins, A. Korhonen, K. Dreij, L. Al-Anati, and J. Hogberg Exocrine pancreatic carcinogenesis and autotaxin expression PLoS One 7 2012 e43209
245. A.L. Parrill, and D.L. Baker Autotaxin inhibition: challenges and progress toward novel anti-cancer agents Anti-cancer agents in medicinal chemistry 8 2008 917 923
246. A.L. Parrill, and D.L. Baker Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts Expert Opin Ther Pat 20 2010 1619 1625
247. H.M. Albers, and H. Ovaa Chemical evolution of autotaxin inhibitors Chem Rev 112 2012 2593 2603
248. D.C. Budd, and Y. Qian Development of lysophosphatidic acid pathway modulators as therapies for fibrosis Future Med Chem 5 2013 1935 1952
249. G.D. Prestwich, J. Gajewiak, H. Zhang, X. Xu, G. Yang, and M. Serban Phosphatase-resistant analogues of lysophosphatidic acid: agonists promote healing, antagonists and autotaxin inhibitors treat cancer Biochim Biophys Acta 8 2008 8
250. A. Tokumura, M. Miyake, O. Yoshimoto, M. Shimizu, and K. Fukuzawa Metal-ion stimulation and inhibition of lysophospholipase D which generates bioactive lysophosphatidic acid in rat plasma Lipids 33 1998 1009 1015
251. M. Scherer, G. Schmitz, and G. Liebisch High-throughput analysis of sphingosine 1-phosphate, sphinganine 1-phosphate, and lysophosphatidic acid in plasma samples by liquid chromatography-tandem mass spectrometry Clin Chem 55 2009 1218 1222
252. M. Murph, T. Tanaka, J. Pang, E. Felix, S. Liu, and R. Trost Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis Methods Enzymol 433 2007 1 25
253. S. Imamura, and Y. Horiuti Enzymatic determination of phospholipase D activity with choline oxidase J Biochem. 83 1978 677 680
254. H.M. Albers, L.A. van Meeteren, D.A. Egan, E.W. van Tilburg, W.H. Moolenaar, and H. Ovaa Discovery and optimization of boronic acid based inhibitors of autotaxin J Med Chem 53 2010 4958 4967
255. G. Ferry, N. Moulharat, J.P. Pradere, P. Desos, A. Try, and A. Genton S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool J Pharmacol Exp Ther 327 2008 809 819
256. H. Takakusa, K. Kikuchi, Y. Urano, S. Sakamoto, K. Yamaguchi, and T. Nagano Design and synthesis of an enzyme-cleavable sensor molecule for phosphodiesterase activity based on fluorescence resonance energy transfer J Am Chem Soc 124 2002 1653 1657
257. C.G. Ferguson, C.S. Bigman, R.D. Richardson, L.A. van Meeteren, W.H. Moolenaar, and G.D. Prestwich Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity Org Lett 8 2006 2023 2026
258. M. Kawaguchi, T. Okabe, S. Okudaira, H. Nishimasu, R. Ishitani, and H. Kojima Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe ACS Chem Biol 8 2013 1713 1721
259. S. Cavalli, A.J. Houben, H.M. Albers, E.W. van Tilburg, A. de Ru, and J. Aoki Development of an activity-based probe for autotaxin Chembiochem 11 2010 2311 2317
260. T. Clair, E. Koh, M. Ptaszynska, R. Bandle, L. Liotta, and E. Schiffmann L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin Lipids Health Dis 4 2005 5
261. X.W. Liu, D.E. Sok, H.S. Yook, C.B. Sohn, Y.J. Chung, and M.R. Kim Inhibition of lysophospholipase D activity by unsaturated lysophosphatidic acids or seed extracts containing 1-linoleoyl and 1-oleoyl lysophosphatidic acid J Agric Food Chem 55 2007 8717 8722
262. G.G. Durgam, T. Virag, M.D. Walker, R. Tsukahara, S. Yasuda, and K. Liliom Synthesis, structure-activity relationships, and biological evaluation of fatty alcohol phosphates as lysophosphatidic acid receptor ligands, activators of PPARgamma, and inhibitors of autotaxin J Med Chem 48 2005 4919 4930
263. G.G. Durgam, R. Tsukahara, N. Makarova, M.D. Walker, Y. Fujiwara, and K.R. Pigg Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands Bioorg Med Chem Lett 16 2006 633 640
264. V. Gududuru, K. Zeng, R. Tsukahara, N. Makarova, Y. Fujiwara, and K.R. Pigg Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors Bioorg Med Chem Lett 16 2006 451 456
265. D.L. Baker, Y. Fujiwara, K.R. Pigg, R. Tsukahara, S. Kobayashi, and H. Murofushi Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis J Biol Chem 281 2006 22786 22793
266. R. Gupte, A. Siddam, Y. Lu, W. Li, Y. Fujiwara, and N. Panupinthu Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid Bioorg Med Chem Lett 20 2010 7525 7528
267. R. Tanaka, M. Kato, T. Suzuki, A. Nakazaki, E. Nozaki, and M. Gotoh Efficient synthesis of 3-O-thia-cPA and preliminary analysis of its biological activity toward autotaxin Bioorg Med Chem Lett 21 2011 4180 4182
268. E. Nozaki, M. Gotoh, S. Hanazawa, H. Mori, S. Kobayashi, and K. Murakami-Murofushi Comparison of Inhibitory Activities of Stereo-Isomers of Cyclic Phosphatidic Acid (cPA) on Autotaxin Cytologia 76 2011 73 80
269. E. Nozaki, M. Gotoh, R. Tanaka, M. Kato, T. Suzuki, and A. Nakazaki Pharmacological evaluation of a novel cyclic phosphatidic acid derivative 3-S-cyclic phosphatidic acid (3-S-cPA) Bioorg Med Chem 20 2012 3196 3201
270. M.K. Altman, V. Gopal, W. Jia, S. Yu, H. Hall, and G.B. Mills Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid Mol Cancer 9 2010 140
271. E. Gendaszewska-Darmach, E. Laska, P. Rytczak, and A. Okruszek The chemical synthesis of metabolically stabilized 2-OMe-LPA analogues and preliminary studies of their inhibitory activity toward autotaxin Bioorg Med Chem Lett 22 2012 2698 2700
272. L.J. Scott Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis CNS Drugs 25 2011 673 698
273. L.A. van Meeteren, V. Brinkmann, J.S. Saulnier-Blache, K.R. Lynch, and W.H. Moolenaar Anticancer activity of FTY720: Phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D Cancer Lett 266 2008 203 208
274. W.J. Valentine, G.N. Kiss, J.E.S. Liu, M. Gotoh, and K. Murakami-Murofushi (S)-FTY720-vinylphosphonate, an analogue of the immunosuppressive agent FTY720, is a pan-antagonist of sphingosine 1-phosphate GPCR signaling and inhibits autotaxin activity Cell Signal 22 2010 1543 1553
275. P. Cui, J.L. Tomsig, W.F. McCalmont, S. Lee, C.J. Becker, and K.R. Lynch Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors Bioorg Med Chem Lett 17 2007 1634 1640
276. P. Cui, W.F. McCalmont, J.L. Tomsig, K.R. Lynch, and T.L. Macdonald Alpha- and beta-substituted phosphonate analogs of LPA as autotaxin inhibitors Bioorg Med Chem 16 2008 2212 2225
277. G. Jiang, Y. Xu, Y. Fujiwara, T. Tsukahara, R. Tsukahara, and J. Gajewiak Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA ChemMedChem 2 2007 679 690
278. H. Zhang, X. Xu, J. Gajewiak, R. Tsukahara, Y. Fujiwara, and J. Liu Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo Cancer Res 69 2009 5441 5449
279. X. Xu, G. Yang, H. Zhang, and G.D. Prestwich Evaluating dual activity LPA receptor pan-antagonist/autotaxin inhibitors as anti-cancer agents in vivo using engineered human tumors Prostaglandins Other Lipid Mediat 89 2009 140 146
280. G. Jiang, D. Madan, and G.D. Prestwich Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin Bioorg Med Chem Lett 21 2011 5098 5101
281. N. Fisher, T. Hilton-Bolt, M.G. Edwards, K.J. Haxton, M. McKenzie, and S.M. Allin Dendrimer conjugate of [4-(tetradecanoylamino)benzyl]phosphonic acid (S32826) as an autotaxin inhibitor ACS Med Chem Lett 5 2014 34 39
282. R. Gupte, R. Patil, J. Liu, Y. Wang, S.C. Lee, and Y. Fujiwara Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity ChemMedChem 6 2011 922 935
283. R. Leblanc, and O. Peyruchaud New insights in the autotaxin/LPA axis in cancer development and metastasis Exp Cell Res 2014 10.1016/j.yexcr.2014.11.010
284. H.M. Albers, A. Dong, L.A. van Meeteren, D.A. Egan, M. Sunkara, and E.W. van Tilburg Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation Proc Natl Acad Sci U S A 107 2010 7257 7262
285. H.M. Albers, L.J. Hendrickx, R.J. van Tol, J. Hausmann, A. Perrakis, and H. Ovaa Structure-based design of novel boronic acid-based inhibitors of autotaxin J Med Chem 54 2011 4619 4626
286. S.R. Bhave, D.Y. Dadey, R.M. Karvas, D.J. Ferraro, R.P. Kotipatruni, and J.J. Jaboin Autotaxin inhibition with PF-8380 enhances the radiosensitivity of human and murine glioblastoma cell lines Front Oncol 3 2013 236
287. P.D. St-Coeur, D. Ferguson, P. Morin Jr., and M. Touaibia PF-8380 and closely related analogs: synthesis and structure-activity relationship towards autotaxin inhibition and glioma cell viability Arch Pharm (Weinheim) 346 2013 91 97
288. Merck Patent GMBH. Piperidine and piperazine derivatives. WO2009046841A2.
289. Merck Patent GMBH. Heterocyclic compounds as autotaxin inhibitors. WO2010112116A1.
290. Merck Patent GMBH. Piperidine and piperazine derivatives as autotaxin inhibitors. WO2010115491A2.
291. A.L. Parrill, U. Echols, T. Nguyen, T.C. Pham, A. Hoeglund, and D.L. Baker Virtual screening approaches for the identification of non-lipid autotaxin inhibitors Bioorg Med Chem 16 2008 1784 1795
292. A.B. Hoeglund, A.L. Howard, I.W. Wanjala, T.C. Pham, A.L. Parrill, and D.L. Baker Characterization of non-lipid autotaxin inhibitors Bioorg Med Chem 18 2010 769 776
293. A.B. Hoeglund, H.E. Bostic, A.L. Howard, I.W. Wanjala, M.D. Best, and D.L. Baker Optimization of a pipemidic acid autotaxin inhibitor J Med Chem 53 2010 1056 1066
294. Merck Patent GMBH. Autotaxin inhibitors. WO2010112124A1.
295. Merck Patent GMBH. Imidazole derivatives. WO2009046804A1.
296. Merck Patent GMBH. Benzonaphthyridine compounds used as inhibitors of autotaxin. WO2010060532A1.
297. Merck Patent GMBH. Benzonaphthyridinamines as autotaxin inhibitors. WO2011116867A1.
298. Merck Patent GMBH. Heterocyclic compounds as autotaxin inhibitors. WO2011006569A1.
299. Amira Pharmaceuticals Inc., Autotaxin inhibitors and uses thereof. WO2012024620A2.
300. Amira Pharmaceuticals Inc., Heterocyclic autotaxin inhibitors and uses thereof. WO2012166415A1.
301. Pfizer Limited. Pyridazine derivatives useful in therapy. WO2013061297A1.
302. Pfizer Inc., Pyrimidine and pyridine derivatives useful in therapy. WO2013054185A1.
303. Eli Lilly and Company. Pyrido- or pyrrolo-fused pyrimidine derivatives as autotaxin inhibitors for treating pain. WO2014110000A1.
304. Eli Lilly and Company. Dihydropyrido pyrimidine compounds as autotaxin inhibitors. WO2014168824A1.
305. Biogen Idec Inc. ATX modulating agents. WO2014018881A1.
306. H. Saga, A. Ohhata, A. Hayashi, M. Katoh, T. Maeda, and H. Mizuno A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension PLoS One 9 2014 e93230
307. M.G. Benesch, X. Tang, T. Maeda, A. Ohhata, Y.Y. Zhao, and B.P. Kok Inhibition of autotaxin delays breast tumor growth and lung metastasis in mice FASEB J 28 2014 2655 2666
308. L.P. Saunders, A. Ouellette, R. Bandle, W.C. Chang, H. Zhou, and R.N. Misra Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion Mol Cancer Ther 7 2008 3352 3362
309. H. Hozumi, R. Hokari, C. Kurihara, K. Narimatsu, H. Sato, and S. Sato Involvement of autotaxin/lysophospholipase D expression in intestinal vessels in aggravation of intestinal damage through lymphocyte migration Lab Invest 93 2013 508 519
310. E.J. North, A.L. Howard, I.W. Wanjala, T.C. Pham, D.L. Baker, and A.L. Parrill Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors J Med Chem 53 2010 3095 3105
311. J.I. Fells, S.C. Lee, Y. Fujiwara, D.D. Norman, K.G. Lim, and R. Tsukahara Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface Mol Pharmacol 84 2013 415 424
312. J.I. Fells, S.C. Lee, D.D. Norman, R. Tsukahara, J.R. Kirby, and S. Nelson Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif FEBS J 281 2013 1017 1028
313. S.H. Hwang, B.H. Lee, H.J. Kim, H.J. Cho, H.C. Shin, and K.S. Im Suppression of metastasis of intravenously-inoculated B16/F10 melanoma cells by the novel ginseng-derived ingredient, gintonin: involvement of autotaxin inhibition Int J Oncol 42 2013 317 326
314. K. Ueda, M. Yoshihara, M. Nakao, T. Tanaka, S. Sano, and K. Fukuzawa Evaluation of inhibitory actions of flavonols and related substances on lysophospholipase d activity of serum autotaxin by a convenient assay using a chromogenic substrate J Agric Food Chem 58 2010 6053 6063
315. M. David, J. Ribeiro, F. Descotes, C.M. Serre, M. Barbier, and M. Murone Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis Int J Oncol 40 2012 1133 1141
316. G.N. Kiss, S.C. Lee, J.I. Fells, J. Liu, W.J. Valentine, and Y. Fujiwara Mitigation of radiation injury by selective stimulation of the LPA(2) receptor Biochim Biophys Acta 1831 2013 117 125
317. M. Komachi, K. Sato, M. Tobo, C. Mogi, T. Yamada, and H. Ohta Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo Cancer Sci 103 2012 1099 1104